MT 1013
Alternative Names: MT-1013Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Shaanxi Micot Technology Co
- Class Peptides
- Mechanism of Action Calcium-sensing receptor agonists; Parathyroid hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Secondary hyperparathyroidism
- No development reported Calcium metabolism disorders; Phosphorus metabolism disorders
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Calcium-metabolism-disorders(In volunteers) in USA (Parenteral, Injection)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Phosphorus metabolism disorders(In volunteers) in USA (Parenteral, Injection)
- 18 Nov 2024 Phase-II clinical trials in Secondary hyperparathyroidism in China (IV) (NCT06690242)